Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT00809211 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NETWORK

Sponsor class

Conditions

Leukemia

Interventions

DRUG: nilotinib
GENETIC: cytogenetic analysis
GENETIC: mutation analysis
GENETIC: polymerase chain reaction
OTHER: pharmacological study

Sponsor

Cancer Trials Ireland